Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
INDERIDE LA 160/50 is a fixed-dose combination of propranolol hydrochloride (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic) in extended-release capsule form. It is indicated for hypertension management, combining two complementary mechanisms to reduce blood pressure. This combination therapy targets patients requiring dual antihypertensive action for improved efficacy and medication adherence.
With LOE approaching and a competitive pressure score of 30, the brand team is likely in defensive/maintenance mode, focusing on customer retention and generic transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job postings and LOE approaching, this product offers limited career growth opportunities and is typically staffed at maintenance levels. Working on INDERIDE LA positions you in a defensive, cost-management-focused role rather than driving innovation or market expansion.
Worked on INDERIDE LA 160/50 at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.